Zhang Jingsong, Chadha Juskaran S
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Cancers (Basel). 2024 Sep 6;16(17):3098. doi: 10.3390/cancers16173098.
There is an unmet need to develop new treatments for metastatic prostate cancer. With the development of targeted radioligand therapies, bispecific T cell engagers, antibody-drug conjugates and chimeric antigen receptor T cell (CAR T) therapies, tumor-associated cell surface antigens have emerged as new therapeutic targets in metastatic prostate cancer. Ongoing and completed clinical trials targeting prostate-specific membrane antigen (PSMA), six transmembrane epithelial antigens of the prostate 1 (STEAP1), kallikrein-related peptidase 2 (KLK2), prostate stem cell antigen (PSCA), and delta-like protein 3 (DLL3) in metastatic prostate cancer were reviewed. Strategies for sequential or combinational therapy were discussed.
开发转移性前列腺癌的新治疗方法存在未满足的需求。随着靶向放射性配体疗法、双特异性T细胞衔接器、抗体-药物偶联物和嵌合抗原受体T细胞（CAR T）疗法的发展，肿瘤相关细胞表面抗原已成为转移性前列腺癌的新治疗靶点。本文综述了针对转移性前列腺癌中前列腺特异性膜抗原（PSMA）、前列腺六跨膜上皮抗原1（STEAP1）、激肽释放酶相关肽酶2（KLK2）、前列腺干细胞抗原（PSCA）和δ样蛋白3（DLL3）的正在进行和已完成的临床试验。还讨论了序贯或联合治疗策略。
